A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2019
Price : $35 *
At a glance
- Drugs Merestinib (Primary) ; Cisplatin; Gemcitabine
- Indications Biliary cancer; Carcinoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly and Company; Eli Lilly Japan
- 04 Jun 2019 Planned primary completion date changed from 28 Jun 2019 to 20 Jun 2019.
- 15 Mar 2019 Planned End Date changed from 2 Aug 2019 to 31 Mar 2020.
- 15 Mar 2019 Planned primary completion date changed from 2 Aug 2019 to 28 Jun 2019.